About biogen inc. - BIIB
BIIB At a Glance
| Phone | 1-617-679-2000 | Revenue | 9.27B | |
| Industry | Pharmaceuticals: Major | Net Income | 1.63B | |
| Sector | Health Technology | Employees | 7,605 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BIIB Valuation
| P/E Current | 11.739 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.669 |
| Price to Sales Ratio | 2.408 |
| Price to Book Ratio | 1.334 |
| Price to Cash Flow Ratio | 7.759 |
| Enterprise Value to EBITDA | 9.528 |
| Enterprise Value to Sales | 2.876 |
| Total Debt to Enterprise Value | 0.252 |
BIIB Efficiency
| Revenue/Employee | 1,218,487.837 |
| Income Per Employee | 214,621.959 |
| Receivables Turnover | 4.959 |
| Total Asset Turnover | 0.338 |
BIIB Liquidity
| Current Ratio | 1.349 |
| Quick Ratio | 0.904 |
| Cash Ratio | 0.43 |
BIIB Profitability
| Gross Margin | 67.803 |
| Operating Margin | 22.923 |
| Pretax Margin | 20.568 |
| Net Margin | 17.614 |
| Return on Assets | 5.947 |
| Return on Equity | 10.358 |
| Return on Total Capital | 6.965 |
| Return on Invested Capital | 7.49 |
BIIB Capital Structure
| Total Debt to Total Equity | 40.181 |
| Total Debt to Total Capital | 28.664 |
| Total Debt to Total Assets | 23.946 |
| Long-Term Debt to Equity | 29.204 |
| Long-Term Debt to Total Capital | 20.833 |
Biogen Inc. in the News
FDA to decide on full approval of Alzheimer's treatment Leqembi in early July
The FDA will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said.
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says
A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities."
Biogen picks new CEO, veteran pharmaceutical leader Christopher Viehbacher
Biopharmaceutical company Biogen has picked a new CEO, former Sanofi CEO Christopher Viehbacher, amid fallout from its failed Alzheimer's drug launch.
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drug
Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Biogen investigates death of patient who took Alzheimer’s drug
Biogen said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm.
iPhones may soon detect depression, autism, and cognitive decline: report
Apple is working on features designed to detect depression, anxiety, autism and the cognitive decline that can develop into Alzheimer’s and other kinds of dementia, according to a Tuesday report in the Wall Street Journal.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.
Panel says Biogen's Aduhelm Alzheimer's drug shows no benefit
An expert panel unanimously voted that Biogen’s controversial Alzheimer’s drug does not provide more benefit to patients than supportive care.
FDA chief calls for investigation into Biogen Alzheimer's drug approval process
The Food and Drug Administration’s acting commissioner, Janet Woodcock, is taking the highly unusual step of asking for a federal investigation of doctors within her own agency who met with the makers of an Alzheimer’s drug prior to the medicine’s FDA approval.
FDA trims use of contentious Alzheimer's drug amid backlash
U.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug.